September 27, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be ‘repurposed’ to design new treatments for future cancer therapies. The research, published in Science Signaling, focuses on a protein called TRIB2, which is linked to promoting survival and drug resistance in […]
